Reference
Oliva S, 2012 Italy
Study Objectives
Efficacy of L. reuteri administered as a daily rectal enema in children with distal ulcerative colitis, 6-18 years old. The disease was mild to moderate in activity at entry, and mesalazine was concomitant treatment
Study Design*
R, DB, PC 8 weeks
No. of Subjects (dose)
L. reuteri: 16 Placebo: 15 (1×1010 CFU)
Results
Compared to baseline values, the Mayo Disease Activity Index was significantly decreased in the L. reuteri group compared to placebo at 8 weeks. Within the L. reuteri group the histologi cal score of rectal epithelium was significantly decreased. The levels of proinflammatory cytokines were downregulated while the anti-inflammatory IL-10 was upregulated.